Thermo Fisher raises 2026 outlook after strongest growth since 2021

Overview

Updated Sep 17

Thermo Fisher Scientific grew 5% organically in the second quarter, its fastest pace since 2021. The company raised its full-year guidance and its chief executive says orders are running ahead of revenue.

Thermo Fisher is the largest supplier of laboratory equipment, reagents and services to drug researchers worldwide. Its order book is a leading indicator for pharma and biotech spending, which stalled through 2023 and 2024 before rebuilding as biotech funding conditions recovered.

Why it matters

Thermo Fisher is the biggest supplier to drug research labs. Its accelerating orders mean pharma and biotech are spending again, after years of cutbacks.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

Q2 2026 organic revenue growth

Strongest quarterly organic growth since 2021.

$11.99B

Q2 2026 revenue

Up 10% reported versus $10.85 billion a year earlier.

13%

Q2 2026 adjusted EPS growth

Adjusted earnings per share rose double digits in the quarter.

~4%

Full-year 2026 organic growth forecast

Upper end of the 3% to 4% range management guided to.

Voices

Curated perspectives — historical figures and your fellow readers.

People Involved

Marc N. Casper

Chairman and chief executive officer, Thermo Fisher Scientific

Leading the company through its demand recovery

Donald Trump

President of the United States

Promoting U.S. pharmaceutical manufacturing

Organizations Involved

Thermo Fisher Scientific Inc.

Life sciences tools and services company

Raised 2026 guidance after 5% organic Q2 growth

World's largest supplier of laboratory equipment, reagents and services to drug researchers.

Timeline

March 2026 September 2026

3 events Latest: September 17th, 2026 · 2 months ago

September 2026
Casper calls 2026 'outstanding year' at Morgan Stanley conference
Latest Statement

CEO Marc Casper told investors orders are running ahead of revenue and reaffirmed roughly 4% full-year organic growth, expecting a similar pace in Q3 and Q4.
September 17th, 2026
July 2026
Thermo Fisher posts 5% organic growth, raises 2026 outlook
Earnings

Q2 revenue rose 10% to $11.99 billion with 5% organic growth, the strongest since 2021. Adjusted EPS grew 13%. Full-year revenue guidance was raised to $47.4-48.1 billion.
July 23rd, 2026
March 2026
Trump tours Thermo Fisher's Cincinnati plant in March
Event

President Trump visited the company's contract manufacturing site in Cincinnati, part of the administration's push to bring drug production back to the U.S.
March 2026

Scenarios

Thermo Fisher lands 2026 at or above 4% organic growth

Likely Resolves by Feb 15, 2027

Discussed by: Company guidance, reaffirmed by CEO Marc Casper at Morgan Stanley's September conference

Thermo Fisher expects roughly 4% organic growth in both Q3 and Q4. Orders are running ahead of revenue, and pharma customers are investing in drug pipelines with AI-assisted development. If momentum holds, the company finishes the year inside or above its raised guidance.

2027 guidance shows growth accelerating above 6%

Possible Resolves by Feb 15, 2027

Discussed by: Company statements on reshoring and biotech funding translating into revenue

Casper says U.S. pharmaceutical reshoring will drive expansions of existing facilities mainly in 2027, and new plants in 2027-2028. Continued biotech funding recovery also feeds through to revenue. If both play out, 2027 guidance would exceed 6% organic growth.

Biotech funding stalls and organic growth slips toward 3%

Unlikely Resolves by Jul 31, 2027

Discussed by: A cautious reading of the cycle; Casper notes funding takes two to three quarters to reach revenue

Venture capital, IPO and M&A activity in biotech could cool again as it did in 2022-2024. That would slow the translation of current order momentum into sustained revenue, keeping growth near the low end of Thermo Fisher's 3-6% range.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2020-2023

COVID testing boom and bust (2020-2023)

Thermo Fisher's COVID diagnostics revenue surged during the pandemic, peaking alongside global testing demand. When testing collapsed in 2022-2023, the company swung to negative organic growth as that revenue vanished.

Then

The company cut costs and refocused on academic, pharma and bioprocessing markets.

Now

The episode showed how volatile demand can be in life-sciences tools, with a single end market able to swing results dramatically.

Why this matters now

It explains why 2026's 5% organic growth matters: it is the strongest since the COVID-era peak, marking a genuine recovery rather than a small uptick.

2008-2010

Biotech funding freeze after the 2008 financial crisis (2008-2010)

Venture funding for biotech startups dried up during the financial crisis, cutting orders at research toolmakers. Clinical research spending was hit first, then laboratory supplies and reagents.

Then

Toolmakers saw roughly two years of flat or falling revenue before funding recovered.

Now

The recovery followed a predictable sequence: clinical research spending first, then lab supplies, then high-tech reagents.

Why this matters now

Casper described the same sequence in 2026: biotech funding takes two to three quarters to translate into revenue, showing up in clinical research before lab supplies.

2015-2016

The 2015-2016 biotech slowdown

Biotech stocks peaked in mid-2015 then tumbled on drug pricing concerns and slowing China demand. Toolmakers including Thermo Fisher saw growth decelerate sharply.

Then

Instrument and reagent spending slowed for several quarters before recovering in 2017.

Now

The cycle showed life-sciences demand tends to recover within two years of a funding shock.

Why this matters now

Mirrors the 2022-2024 slump and 2026 rebound, where funding-driven demand returned faster than the initial downturn suggested.